Want to see NVCT full AI Analyst Report?
NVCT Stock Chart & Stats
$19.31
$0.12(0.62%)
At close: 4:00 PM EDT
$19.31
$0.12(0.62%)
Day’s Range― - ―
52-Week Range$5.55 - $29.28
Previous CloseN/A
Volume13.30K
Average Volume (3M)89.48K
Market Cap
$760.78M
Enterprise Value$409.56
Total Cash (Recent Filing)$22.16M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Nov 10, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.31
Shares Outstanding32,581,530
10 Day Avg. Volume112,705
30 Day Avg. Volume89,483
Financial Highlights & Ratios
PEG Ratio-0.30
Price to Book (P/B)8.94
Price to Sales (P/S)0.00
P/FCF Ratio-10.29
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$34.00Price Target Upside76.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetNo reported debt reduces solvency risk and interest obligations, giving Nuvectis greater flexibility to direct capital toward clinical development. This is particularly valuable for a pre-revenue biotech that must fund programs before generating product income.
Expanded Clinical PipelineThe Haisco transaction broadens Nuvectis beyond its existing oncology programs into complement-mediated diseases and BRAF-mutated cancers. Multiple clinical-stage assets could diversify development outcomes and create additional long-term commercial opportunities.
Enhanced Development FundingThe sizable equity raise strengthens near-term funding capacity for NXP100, NXP200 and NXP900, as well as staffing and operating needs. Greater financial resources can support continued trials and reduce the risk of development delays caused by insufficient capital.
Bears Say
Pre-Revenue Business ModelWith no product revenue, Nuvectis has not yet demonstrated commercial demand or product economics. Persistent losses mean future value depends on clinical and regulatory execution, leaving the business exposed to setbacks before recurring revenue can develop.
Persistent Cash BurnSustained negative cash generation requires Nuvectis to repeatedly access financing to fund research, trials and corporate costs. The worsening TTM burn compared with 2025 and 2024 increases dependence on capital markets and could constrain strategic flexibility.
Equity Financing And Dilution RiskThe ATM provides financing flexibility but also creates a durable dilution risk because additional shares may be issued while the company remains loss-making and cash-burning. Reliance on equity funding can reduce existing holders’ ownership of future pipeline value.
Nuvectis Pharma News
NVCT FAQ
What was Nuvectis Pharma’s price range in the past 12 months?
Nuvectis Pharma lowest stock price was $5.55 and its highest was $29.27 in the past 12 months.
What is Nuvectis Pharma’s market cap?
Nuvectis Pharma’s market cap is $760.78M.
When is Nuvectis Pharma’s upcoming earnings report date?
Nuvectis Pharma’s upcoming earnings report date is Nov 10, 2026 which is in 79 days.
How were Nuvectis Pharma’s earnings last quarter?
Nuvectis Pharma released its earnings results on Aug 04, 2026. The company reported -$0.3 earnings per share for the quarter, missing the consensus estimate of -$0.262 by -$0.038.
Is Nuvectis Pharma overvalued?
According to Wall Street analysts Nuvectis Pharma’s price is currently Undervalued.
Does Nuvectis Pharma pay dividends?
Nuvectis Pharma does not currently pay dividends.
What is Nuvectis Pharma’s EPS estimate?
Nuvectis Pharma’s EPS estimate is -0.23.
How many shares outstanding does Nuvectis Pharma have?
Nuvectis Pharma has 32,581,530 shares outstanding.
What happened to Nuvectis Pharma’s price movement after its last earnings report?
Nuvectis Pharma reported an EPS of -$0.3 in its last earnings report, missing expectations of -$0.262. Following the earnings report the stock price went down -6.944%.
Which hedge fund is a major shareholder of Nuvectis Pharma?
Currently, no hedge funds are holding shares in NVCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nuvectis Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.00 (76.07% Upside)
$34.00 (76.07% Upside)
Blogger Sentiment
Bullish
NVCT Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
82.74%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-17.15%
Trailing 12-Months
Company Description
Nuvectis Pharma
Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases. This Fort Lee, New Jersey-based organization was established in 2020.
NVCT Stock 12 Month Forecast
Average Price Target
$34.00
▲(76.07% Upside)
Technical Analysis
Nkarta
―
Orchestra BioMed Holdings
―
Greenwich LifeSciences
―
Molecular Partners
―
Pyxis Oncology
―
Ownership Overview
34.92% Insiders
3.61% Mutual Funds
18.17% Other Institutional Investors
37.61% Public Companies and
Individual Investors